Alebund Pharmaceuticals gets FDA IND clearance for AP308 in IgA nephropathy
FDA clears Alebund’s AP308 for human testing in IgA nephropathy, taking a novel IgA-cleaving strategy beyond promising preclinical data.
Pharma & Biotech
Pharma & Biotech
FDA clears Alebund AP308 IND for first-in-human IgA nephropathy study
The FDA has cleared Alebund Pharmaceuticals’ AP308 IND, allowing a first-in-human study of an engineered IgA protease designed to remove pathogenic IgA and immune complexes in IgA nephropathy.